Samsung Biologics, South Korea-based contract development and manufacturing organisation (CDMO), and Kurma Partners, a European venture capital firm in healthcare and biotechnology, have announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners' portfolio companies.

Under the terms of the multi-year agreement, Samsung Biologics will provide customisable chemistry, manufacturing, and control (CMC) development services for Kurma Partners' portfolio companies to streamline the gene to Investigational New Drug (IND) process, de-risk uncertainties in CMC, and accelerate the lead candidate selection through entry into first-in-human studies with seamless transitions along further clinical development. The portfolio companies will be able to leverage Samsung Biologics' state-of-the-art facilities, proprietary technology platforms, and CMC-related expertise.

The latest agreement reflects Samsung Biologics' continued commitment to support emerging biotech companies on their drug development and manufacturing journey as well as further increase its business presence in major sectors with a focus on the US and European markets.